التفاصيل البيبلوغرافية
| العنوان: |
Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon-like peptide-1 secretion and expression in intestinal cells. |
| المؤلفون: |
Chen, Fei‐Fei, Wang, Jian‐Ta, Zhang, Li‐Xia, Xing, Shu‐Fang, Wang, Yun‐Xia, Wang, Kai, Deng, Shu‐Li, Zhang, Ji‐Quan, Tang, Lei, Wu, Hao‐Shu, Chen, Fei-Fei, Wang, Jian-Ta, Zhang, Li-Xia, Xing, Shu-Fang, Wang, Yun-Xia, Deng, Shu-Li, Zhang, Ji-Quan, Wu, Hao-Shu |
| المصدر: |
British Journal of Pharmacology; Sep2017, Vol. 174 Issue 17, p2912-2928, 17p |
| مصطلحات موضوعية: |
GLUCAGON-like peptide 1, TREATMENT of diabetes, ALANINE aminotransferase, ASPARTATE aminotransferase, BLOOD sugar, ISLANDS of Langerhans, LIVER lipids, CYTOKINES, THERAPEUTICS, BLOOD sugar analysis, STEROID drugs, ANIMAL experimentation, BODY weight, CELL lines, CYCLIC adenylic acid, DIABETES, EPITHELIAL cells, GENETIC disorders, HYPOGLYCEMIC agents, LIPID metabolism disorders, LIVER, MICE, MOLECULAR structure, OBESITY, PANCREAS, PREVENTIVE health services, STEROIDS, TRANSFERASES, PHARMACODYNAMICS |
| مستخلص: |
Background and Purpose: Glucagon-like peptide-1 (GLP-1) is an important target for diabetes therapy based on its key role in maintaining glucose and lipid homeostasis. This study was designed to investigate antidiabetic and hepatoprotective effects of a novel oleanolic acid derivative DKS26 in diabetic mice and elucidate its underlying GLP-1 related antidiabetic mechanisms in vitro and in vivo.Experimental Approach: The therapeutic effects of DKS26 were investigated in streptozotocin (STZ)-induced and db/db diabetic mouse models. Levels of plasma glucose, glycosylated serum protein (GSP), lipid profiles, insulin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), oral glucose tolerance (OGT), pancreatic islets and hepatic histopathological morphology, liver lipid levels and expression of pro-inflammatory cytokines were assessed. Intestinal NCI-H716 cells and diabetic models were used to further validate its potential GLP-1-related antidiabetic mechanisms.Key Results: DKS26 treatment (100 mg·kg-1 ·day-1 ) decreased plasma levels of glucose, GSP, ALT and AST; ameliorated OGT and plasma lipid profiles; augmented plasma insulin levels; alleviated islets and hepatic pathological morphology; and reduced liver lipid accumulation, inflammation and necrosis in vivo. Furthermore, DKS26 enhanced GLP-1 release and expression, accompanied by elevated levels of cAMP and phosphorylated PKA in vitro and in vivo.Conclusion and Implications: DKS26 exerted hypoglycaemic, hypolipidaemic and islets protective effects, which were associated with an enhanced release and expression of GLP-1 mediated by the activation of the cAMP/PKA signalling pathway, and alleviated hepatic damage by reducing liver lipid levels and inflammation. These findings firmly identified DKS26 as a new viable therapeutic option for diabetes control. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder